根据一份提交给美国证券交易委员会(SEC)的文件显示,生物技术公司Precision Biosciences Inc(简称:Precision)预计将在2026年底前获得其针对杜氏肌营养不良症(DMD)的基因编辑疗法Function-DMD临床试验的初步安全性数据。该文件明确了这一关键里程碑的时间目标。
根据一份提交给美国证券交易委员会(SEC)的文件显示,生物技术公司Precision Biosciences Inc(简称:Precision)预计将在2026年底前获得其针对杜氏肌营养不良症(DMD)的基因编辑疗法Function-DMD临床试验的初步安全性数据。该文件明确了这一关键里程碑的时间目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.